Purpose, strategy and culture

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.

We are a company where outstanding people can thrive.

Our strategy

GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology.

 

Our R&D approach

Partner with GSK

Our portfolio

Shingles cell

Vaccines

Vaccines

Vaccines help protect people from infectious diseases at every stage of life. Our vaccines portfolio is the broadest in the industry, helping protect people from meningitis, shingles, flu, polio, measles and many more. Today, one and a half million doses of our vaccines are administered daily, and around 40% of the world’s children receive a GSK jab each year. We use diverse platform technologies from adjuvants that improve vaccine effectiveness through to mRNA technology. These are at the heart of our pipeline differentiation.

HIV virus science image

Specialty medicines

Specialty medicines

Specialty medicines are prescribed by specialist healthcare practitioners. For GSK this includes our cancer medicines that have life-changing potential for patients. We’re also developing medicines for immune-mediated conditions, including the first new medicine for the chronic autoimmune condition lupus in over 50 years.

We are global leaders in developing medicines for HIV. Having pioneered the first HIV treatments in the 1980s, our goal now is to limit the impact of HIV on people’s lives by treating, preventing and ultimately curing it.

GSK E.Coli

General medicines

General medicines

General medicines are usually prescribed in primary care or community settings by general healthcare practitioners. For us, this includes our inhaled medicines for asthma and COPD, antibiotics and medicines for skin diseases. Every day, these medicines improve health and make life better for millions of people all over the world. For more than 50 years, we’ve helped millions of people with respiratory conditions to breathe more easily, including the first inhalers in 1969, and we remain the industry leader in respiratory science.

Our therapeutic areas

RSV virus cell

Infectious diseases

Infectious diseases

Two thirds of the vaccines and medicines in our pipeline address infectious diseases, helping protect people from diseases like meningitis, shingles, flu, polio, measles and many more.

HIV cell

HIV

HIV

Our goal is to minimise the impact of HIV on people’s lives through treatment, prevention and ultimately cure.

Lupus cells

Respiratory/ immunology

Respiratory/ immunology

We’re focused on unlocking the science of the immune system to understand how the body reacts.

Immuno oncology science image

Oncology

Oncology

Our expertise in oncology allows us to bring groundbreaking cancer therapies to our patients.

DNA strand graphic

Opportunity-driven

Opportunity-driven

As well as our portfolio across therapy areas, we pursue other opportunities where the emerging science indicates the potential for important new opportunities to have major impact in addressing unmet need. This includes the work we are doing to help the one in seven of 700 million chronic kidney disease sufferers with anaemia.

Our long-term priorities

Innovation
Scientist smiling
  • New approvals since 2017

    20+
  • Potential new vaccines and medicines in phase III and registration since 2017

    23
  • Vaccines and medicines in our pipeline

    68
Performance
Scientist in Smart Lab
  • Patients: packs of medicines and doses of vaccines delivered in 2022

    2.3bn
  • Shareholders: per share dividend in 2022

    61.25p
  • Society: corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes

    £1.3bn
Trust
Lab worker smiling

Our culture

Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we’ll deliver for patients, shareholders and GSK people.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

 

Meet our Outstanding people

6:45

Innovating together

Meet Geeta – finding inspiration by making a difference

18 July 2022
0:55

My GSK story

Meet Samuel: helping get medicines to our patients

25 October 2022
2:44

Working together

Meet Jess: advocating for patients

02 November 2022

GSKH team member

WHAT’S YOUR ANGLE?

Our film series brings together our people from teams across the world to discuss the issues that matter across the themes of diversity, equity and inclusion, and explore their different perspectives.